Mechanisms of Hypercalcemia in non-Hodgkin Lymphoma and Associated Outcomes: a Retrospective Review

The etiology of hypercalcemia in non-Hodgkin lymphoma (NHL) is most often attributed to either elevated serum levels of 1,25-dihydroxycholecalciferol (calcitriol) or parathyroid-related protein (PTHrP). In a single center retrospective review we evaluated the incidence of and outcomes associated with hypercalcemia in NHL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

ConclusionThe ability to correctly identify bone marrow involvement utilizing FDG PET/CT based voxel analysis provides promise as a novel non-invasive method of accurate staging.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): Mayur S. Narkhede, Bruce D. ChesonAbstractFollicular lymphoma is the second most common subtype of non-Hodgkin lymphoma with an estimated 3.18 cases per 100,000 people. Despite the prolongation of survival with chemoimmunotherapy, variability in response to initial treatment and outcome still exists. Whereas prolonging overall survival is important, it is generally an unreasonable primary endpoint in the front-line setting. The long follow-up needed and the influence of subsequent therapies creates a potential bias. Thus...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionThe ability to correctly identify bone marrow involvement utilizing FDG PET/CT based voxel analysis provides promise as a novel non-invasive method of accurate staging.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): Mayur S. Narkhede, Bruce D. ChesonAbstractFollicular lymphoma is the second most common subtype of non-Hodgkin lymphoma with an estimated 3.18 cases per 100,000 people. Despite the prolongation of survival with chemoimmunotherapy, variability in response to initial treatment and outcome still exists. Whereas prolonging overall survival is important, it is generally an unreasonable primary endpoint in the front-line setting. The long follow-up needed and the influence of subsequent therapies creates a potential bias. Thus...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Patients with relapsed/refractory non-Hodgkin lymphoma remain a population with an unmet medical need. Histone deacetylase inhibitors and proteasome inhibitors have shown synergistic interactions preclinically in several B-cell malignancies. The present phase II trial examined the combination of the proteasome inhibitor bortezomib and the histone deacetylase inhibitor vorinostat in patients with relapsed/refractory diffuse large B-cell lymphoma or mantle cell lymphoma. The results of the present trial revealed a modest overall response rate.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
1419Objectives: Non-Hodgkin lymphoma (NHL) cases with inconclusive biopsy findings are not infrequently referred for FDG PET/CT. Maximum standardized uptake value (SUVmax) more than 10 was suggestive of aggressive nature of NHL in previous studies. Now we are checking whether this cut-off differs in the modern time of flight (TOF) PET/CT and its accuracy in comparison with that in conventional non-TOF PET/CT. Methods: : Retrospectively, 328 patients were selected by the following inclusion criteria: biopsy-proven NHL with no more than one histopathological type; new cases with less than 90 days between obtaining biopsy and...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
Plasmablastic lymphoma (PBL) is a rare type of non-Hodgkin lymphoma (NHL) with a predilection for the oral cavity. It is more commonly found in elderly patients infected with HIV and Epstein-Barr virus (EBV). Since PBL was first described in 1997,1 most cases have been described in HIV-positive patients.2 Some instances have been described in HIV-negative patients involving other organs; one third of these occurred in patients treated with some immunosuppressive therapy.3 The scarcity of presentations in HIV-negative patients and the overlapping features with multiple myeloma present a diagnostic and therapeutic challenge.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Primary cutaneous lymphomas are a heterogeneous group of lymphoid malignancies and are the second most common group of extranodal non-Hodgkin lymphoma (NHL) following gastrointestinal lymphomas.1 NHL involving the female genitalia is unusual, posing diagnostic and therapeutic challenges.2-4 Rare cases of vulvar NHL presenting as a vulvar mass were mostly diagnosed as diffuse large B-cell lymphoma and had an aggressive course.3,5 Cases of cutaneous T-cell lymphoma (CTCL) involving the vulva have been rarely reported.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Publication date: Available online 17 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ali Dehghanifard, Saeid Kaviani, Saeid Abroun, Mahshad Mehdizadeh, Sajedeh Saiedi, Amirhosein Maali, Sasan Ghaffari, Mehdi Azad Multiple myeloma (MM) results from malignancy in plasma cells and occurs at ages > 50 years. MM is the second most common hematologic malignancy after non-Hodgkin lymphoma, which constitutes 1% of all malignancies. Despite the great advances in the discovery of useful drugs for this disease such as dexamethasone and bortezomib, it is still an incurable malignancy owing to the development o...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Peripheral blood stem cell transplantation (PBSCT) is an effective treatment for hematological malignancies. Mobilization of peripheral blood stem cells performs in different ways among transplantation centers. Since the Effects of lower CD34+ cells dose after low dose G-CSF induction on autologous stem cell transplantation outcomes are not studied much, so this study was performed for this purpose. 735 autologous stem cell transplanted patients with diagnoses of multiple myeloma (n  = 330), Hodgkin lymphoma (n = 200), non-Hodgkin lymphoma (n = 129), acute myeloid leukemia (n = 54) and solid tumors (n =...
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Study